This $3,055,695 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports the University of Utah's research on developing GJA1-20K as a novel treatment for hemorrhagic shock. The goal is to minimize mitochondrial injury and mitigate ischemia-reperfusion injury. This 4-year project, running from April 2024 through April 2028, will advance innovative biomedical research with potential to improve health outcomes for military service members. The University of Utah, a leading public research institution, is well-positioned to conduct this critical work that aligns with the Defense Health Agency's medical research priorities.
Generated 1/14/25, 8:09 AM